Scoping insight on antiviral drugs against COVID-19.
Arab J Chem
; 14(10): 103385, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1356130
ABSTRACT
BACKGROUND:
COVID-19 is an ongoing viral pandemic produced by SARS-CoV-2. In light of in vitro efficacy, several medications were repurposed for its management. During clinical use, many of these medications produced inconsistent results or had varying limitations.OBJECTIVE:
The purpose of this literature review is to explain the variable efficacy or limitations of Lopinavir/Ritonavir, Remdesivir, Hydroxychloroquine, and Favipiravir in clinical settings.METHOD:
A study of the literature on the pharmacodynamics (PD), pharmacokinetics (PK), safety profile, and clinical trials through academic databases using relevant search terms. RESULTS &DISCUSSION:
The efficacy of an antiviral drug against COVID-19 is associated with its ability to achieve therapeutic concentration in the lung and intestinal tissues. This efficacy depends on the PK properties, particularly protein binding, volume of distribution, and half-life. The PK and PD of the model drugs need to be integrated to predict their limitations.CONCLUSION:
Current antiviral drugs have varying pharmacological constraints that may associate with limited efficacy, especially in severe COVID-19 patients, or safety concerns.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
/
Reviews
Language:
English
Journal:
Arab J Chem
Year:
2021
Document Type:
Article
Affiliation country:
J.arabjc.2021.103385
Similar
MEDLINE
...
LILACS
LIS